A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

BACKGROUND: The combination of everolimus and the imidazoquinoline derivative, BEZ235 (dactolisib), a dual PI3K/mTOR inhibitor, demonstrated synergy in a preclinical model. OBJECTIVE: To establish clinical feasibility, a phase Ib dose-escalation trial investigating safety and pharmacokinetics of thi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Target Oncol
Main Authors: Wise-Draper, Trisha M., Moorthy, Ganesh, Salkeni, Mohamad A., Karim, Nagla Abdel, Thomas, Hala Elnakat, Mercer, Carol A., Beg, M. Shalaan, O’Gara, Sue, Olowokure, Olugbenga, Fathallah, Hassana, Kozma, Sara C., Thomas, George, Rixe, Olivier, Desai, Pankaj, Morris, John C.
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2017
Assuntos:
Original Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5447332/
https://ncbi.nlm.nih.gov/pubmed/28357727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-017-0482-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares